274 related articles for article (PubMed ID: 19944452)
1. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
[TBL] [Abstract][Full Text] [Related]
2. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740
[TBL] [Abstract][Full Text] [Related]
3. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Bell J; Brady MF; Young RC; Lage J; Walker JL; Look KY; Rose GS; Spirtos NM;
Gynecol Oncol; 2006 Sep; 102(3):432-9. PubMed ID: 16860852
[TBL] [Abstract][Full Text] [Related]
6. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
8. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
9. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
11. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
12. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
13. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
[TBL] [Abstract][Full Text] [Related]
14. A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.
Bamias A; Bamia C; Karadimou A; Soupos N; Zagouri F; Rodolakis A; Haidopoulos D; Vlahos G; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2011; 81(5-6):365-71. PubMed ID: 22248920
[TBL] [Abstract][Full Text] [Related]
15. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.
Young RC
Semin Oncol; 2000 Jun; 27(3 Suppl 7):8-10. PubMed ID: 10952120
[TBL] [Abstract][Full Text] [Related]
16. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
17. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
18. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
19. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
20. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]